For the year ending 2025-10-31, ZEOX had -$436K decrease in cash & cash equivalents over the period. -$741K in free cash flow.
| Cash Flow | 2025-10-31 |
|---|---|
| Net loss | -5,521 |
| Depreciation and amortization expense | 73 |
| Amortization of debt discount promissory notes | 39 |
| Bad debt expense | 0 |
| Change in obligation to repurchase shares | 2 |
| Inducement expense to convert notes | 136 |
| Stock-based compensation | 4,693 |
| Accounts receivable, net of allowance for bad debts | -159 |
| Other receivable | -3 |
| Prepaid expenses | 25 |
| Inventories | 191 |
| Accounts payable and accrued expenses | 200 |
| Deferred revenue | -286 |
| Net cash used in operating activities | -718 |
| Purchase of fixed assets | 23 |
| Net cash used in investing activities | -23 |
| Proceeds from exercise of warrants | 50 |
| Payments on finance leases | 45 |
| Proceeds from sale of common stock | 300 |
| Net cash provided by financing activities | 305 |
| Decrease in cash | -436 |
| Cash and cash equivalents at beginning of period | 657 |
| Cash and cash equivalents at end of period | 221 |
Zeo ScientifiX, Inc. (ZEOX)
Zeo ScientifiX, Inc. (ZEOX)